返回排名列表

Thermo Fisher Scientific Inc (TMO)

被高估
HealthcareDiagnostics & ResearchUnited States

基本面

61

价格

$660.82

市值

$250.91B

第一部分 · 这家公司值多少

概览

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$46.34B

最近12个月(截至2026/6/27)

净利润

$6.97B

最近12个月(截至2026/6/27)

自由现金流

$6.29B

股东权益合计

$53.41B

负债合计

$56.93B

流动比率

1.55

利息覆盖率

5.46

债务/EBITDA

3.62

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被高估

公允价值

$437.42

当前价格

$660.82

安全边际

-51.1%

公允价值区间

$284.32 - $590.52

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$653.11
现金流折现法(DCF):$291.26
市盈率法(P/E):$455.96
格雷厄姆成长公式:$207.75
盈利能力价值(EPV):$187.20
合理市净率(P/B):$251.52
股息折现模型(戈登模型):$33.18
P/FFO(运营资金):数据不足,无法计算
周期中段收益:$349.15
市销率法(P/S):$492.07
分析师共识:强力买入 (29B / 7H / 0S)
最近财报超预期:+4.54%

估值指标

市盈率(P/E)

36.31

ROE

12.6%

市净率(P/B)

4.74

P/FCF

34.11

毛利率

-

ROIC

6.6%

盈利能力雷达图

价值创造(经济护城河)

ROIC

6.6%

WACC

8.3%

ROIC − WACC

-1.7 pp

ROIC 低于资本成本:公司每投入一美元都在毁灭价值。

基本面分析标准

通过(19)

  • EPS shows upward trend
  • EPS CAGR 13.95%
  • Price CAGR 15.76%
  • ROIC 6.6%
  • Debt/Equity ratio
  • Operating Margin 17.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 13.3%
  • Revenue Growth 5Y 6.7%
  • Analyst Consensus 81% Buy
  • Earnings Surprise avg 3.2%
  • Earnings Quality (OCF/NI) 1.29
  • Share Dilution -1.4%
  • Piotroski F-Score 5/9

未通过(7)

  • P/FCF 34.11
  • P/B Ratio 4.74
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 16.99
  • Net Margin Trend 15.0% vs 15.2%

不可用(2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-评分

5/9

信号混杂:部分领域需关注

score
criteria

盈利质量

1.29

高质量:盈利有现金流支撑

股权稀释

-1.4%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Mr. Marc N. CasperChairman & CEO57
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies46
Mr. James R. MeyerSenior VP & CFO45
Mr. Joseph R. HolmesVP & Chief Accounting Officer45
Mr. Ryan J. SnyderSenior VP & Chief Information Officer-
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer-
Mr. Rafael TejadaVice President of Investor Relations-
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel-
Ms. Sandy B. PoundVP & Chief Communications Officer-
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development65

审计风险

2

董事会风险

7

薪酬风险

10

股东权利风险

1

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-26

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-07-31

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-07-23

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for TMO, sourced from Markets Gazette.

  • 5/25/2026POSITIVE
    If You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today

    An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.

  • 3/12/2026POSITIVE
    Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

    An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.

  • 3/2/2026NEUTRAL
    Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

    A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.

via Markets Gazette